To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

NCT04955626 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

16372

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection
COVID-19

Interventions

BIOLOGICAL: BNT162b2
OTHER: Placebo
BIOLOGICAL: BNT162b2 OMI
BIOLOGICAL: Combination BNT162b2 and BNT162b2 OMI
BIOLOGICAL: Combination (Bivalent) BNT162b2 and BNT162b2 OMI

Sponsor

BioNTech SE

Collaborators

[object Object]